<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-05-19" updated="2020-01-02">
  <drugbank-id primary="true">DB11596</drugbank-id>
  <name>Levoleucovorin</name>
  <description>Levoleucovorin is the enantiomerically active form of Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin). Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. Despite this difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side effects (Kovoor et al, 2009). &#13;
&#13;
As folate analogs, levoleucovorin and leucovorin are both used to counteract the toxic effects of folic acid antagonists, such as methotrexate, which act by inhibiting the enzyme dihydrofolate reductase (DHFR). They are indicated for use as rescue therapy following use of high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Levoleucovorin, as the product Fusilev (FDA), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. &#13;
&#13;
Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects of methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects.</description>
  <cas-number>68538-85-2</cas-number>
  <unii>990S25980Y</unii>
  <average-mass>473.4393</average-mass>
  <monoisotopic-mass>473.165896125</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18442</ref-id>
        <pubmed-id>19822510</pubmed-id>
        <citation>Kovoor PA, Karim SM, Marshall JL: Is levoleucovorin an alternative to racemic leucovorin? A literature review. Clin Colorectal Cancer. 2009 Oct;8(4):200-6. doi: 10.3816/CCC.2009.n.034.</citation>
      </article>
      <article>
        <ref-id>A18484</ref-id>
        <pubmed-id>2410416</pubmed-id>
        <citation>Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985 Aug 15;260(17):9720-6.</citation>
      </article>
      <article>
        <ref-id>A18485</ref-id>
        <pubmed-id>22332074</pubmed-id>
        <citation>Stover PJ, Field MS: Trafficking of intracellular folates. Adv Nutr. 2011 Jul;2(4):325-31. doi: 10.3945/an.111.000596. Epub 2011 Jun 28.</citation>
      </article>
      <article>
        <ref-id>A18486</ref-id>
        <pubmed-id>23032661</pubmed-id>
        <citation>Chuang VT, Suno M: Levoleucovorin as replacement for leucovorin in cancer treatment. Ann Pharmacother. 2012 Oct;46(10):1349-57. doi: 10.1345/aph.1Q677. Epub 2012 Oct  2.</citation>
      </article>
      <article>
        <ref-id>A18487</ref-id>
        <pubmed-id>8353099</pubmed-id>
        <citation>Zittoun J: Pharmacokinetics and in vitro studies of l-leucovorin. Comparison with the d and d,l-leucovorin. Ann Oncol. 1993;4 Suppl 2:1-5.</citation>
      </article>
      <article>
        <ref-id>A18488</ref-id>
        <pubmed-id>2388292</pubmed-id>
        <citation>Schilsky RL, Ratain MJ: Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 5;82(17):1411-5.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L306</ref-id>
        <title>product info</title>
        <url>http://www.rxlist.com/levoleucovorin-drug/clinical-pharmacology.htm</url>
      </link>
      <link>
        <ref-id>L307</ref-id>
        <title>product info</title>
        <url>http://davisplus.fadavis.com/3976/meddeck/pdf/levoleucovorincalcium.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Levoleucovorin is indicated for use as rescue therapy following high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Levoleucovorin, as the product Fusilev (FDA, dosed at one-half the usual dose of racemic d,l-leucovorin), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer (although they should not be mixed in the same infusion as a precipitate may form).</indication>
  <pharmacodynamics>Levoleucovorin is actively and passively transported across cell membranes. In vivo, levoleucovorin is converted to 5-methyltetrahydrofolic acid (5-methyl-THF), the primary circulating form of active reduced folate. Levoleucovorin and 5-methyl-THF are polyglutamated intracellularly by the enzyme folylpolyglutamate synthetase. Folylpolyglutamates are active and participate in biochemical pathways that require reduced folate.</pharmacodynamics>
  <mechanism-of-action>Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects of methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects.</mechanism-of-action>
  <toxicity>ِAcute intravenous LD50 values in adult mice and rats were 575 mg/kg (1725 mg/m²) and 378 mg/kg ( 2268 mg/m²), respectively.</toxicity>
  <metabolism>Extensively converted to tetrahydrofolic derivatives.</metabolism>
  <absorption>After rapid intravenous administration, serum total tetrahydrofolate (total-THF) concentrations reached a mean peak of 1722 ng/mL. Serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentrations reached a mean peak of 275 ng/mL and the mean time to peak was 0.9 hours. </absorption>
  <half-life>The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.</half-life>
  <protein-binding>Does not bind human serum albumin. </protein-binding>
  <route-of-elimination>Urinary. </route-of-elimination>
  <volume-of-distribution>Data can't be found. </volume-of-distribution>
  <clearance>Data can't be found. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as tetrahydrofolic acids. These are heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with at least one L-glutamic acid unit.</description>
    <direct-parent>Tetrahydrofolic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Pteridines and derivatives</class>
    <subclass>Pterins and derivatives</subclass>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Aminobenzamides</alternative-parent>
    <alternative-parent>Aminopyrimidines and derivatives</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Glutamic acid and derivatives</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hippuric acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenylalkylamines</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Pyrimidones</alternative-parent>
    <alternative-parent>Secondary alkylarylamines</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aminobenzamide</substituent>
    <substituent>Aminobenzoic acid or derivatives</substituent>
    <substituent>Aminopyrimidine</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzamide</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzoic acid or derivatives</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Glutamic acid or derivatives</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hippuric acid</substituent>
    <substituent>Hippuric acid or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>N-acyl-alpha-amino acid</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenylalkylamine</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrimidone</substituent>
    <substituent>Secondary aliphatic/aromatic amine</substituent>
    <substituent>Secondary amine</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Tetrahydrofolic acid</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001886</drugbank-id>
      <name>Levoleucovorin calcium</name>
      <unii>778XL6VBS8</unii>
      <cas-number>80433-71-2</cas-number>
      <inchikey>KVUAALJSMIVURS-QNTKWALQSA-L</inchikey>
      <average-mass>511.508</average-mass>
      <monoisotopic-mass>511.1128369</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001887</drugbank-id>
      <name>Levoleucovorin calcium pentahydrate</name>
      <unii>WA16A5Y52X</unii>
      <cas-number>419573-16-3</cas-number>
      <inchikey>NPPBLUASYYNAIG-BWDMFOMUSA-L</inchikey>
      <average-mass>601.583</average-mass>
      <monoisotopic-mass>601.1656604</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001890</drugbank-id>
      <name>Levoleucovorin disodium</name>
      <unii>5TXQ76K65T</unii>
      <cas-number>1141892-29-6</cas-number>
      <inchikey>FSDMNNPYPVJNAT-NJHZPMQHSA-L</inchikey>
      <average-mass>517.41</average-mass>
      <monoisotopic-mass>517.1297846</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid</synonym>
    <synonym language="english" coder="">(6S)-5-formyltetrahydrofolic acid</synonym>
    <synonym language="english" coder="">(6S)-Folinic acid</synonym>
    <synonym language="english" coder="">(6S)-Leucovorin</synonym>
    <synonym language="english" coder="">(S)-Leucovorin</synonym>
    <synonym language="spanish" coder="">ácido levofolínico</synonym>
    <synonym language="english" coder="">Citrovorum factor</synonym>
    <synonym language="english" coder="">L-Folinic acid</synonym>
    <synonym language="english" coder="">Levofolene</synonym>
    <synonym language="english" coder="">Levofolinic acid</synonym>
    <synonym language="english" coder="iupac">N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid</synonym>
  </synonyms>
  <products>
    <product>
      <name>Fusilev</name>
      <labeller>Spectrum Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68152-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 mg/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020140</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fusilev</name>
      <labeller>Cangene Bio Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>53270-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-15</started-marketing-on>
      <ended-marketing-on>2010-02-24</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 mg/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020140</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fusilev</name>
      <labeller>Acrotech Biopharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>72893-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020140</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fusilev</name>
      <labeller>Acrotech Biopharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>72893-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020140</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fusilev</name>
      <labeller>Spectrum Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68152-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020140</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fusilev</name>
      <labeller>Acrotech Biopharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>72893-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 mg/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020140</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Khapzory</name>
      <labeller>Acrotech Biopharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>72893-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>175 mg/3.5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA211226</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Khapzory</name>
      <labeller>Acrotech Biopharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>72893-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>300 mg/6mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA211226</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Khapzory</name>
      <labeller>Spectrum Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68152-112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>175 mg/3.5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA211226</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Khapzory</name>
      <labeller>Spectrum Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68152-114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>300 mg/6mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA211226</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Fosun Pharma USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72266-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-890</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>175 mg/17.5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-495</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210623</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-4130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-06</started-marketing-on>
      <ended-marketing-on>2019-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA208723</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>West-Ward Pharmaceuticals Corp</labeller>
      <ndc-id/>
      <ndc-product-code>0143-9558</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 mg/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206263</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1099</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA207547</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-494</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210623</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Dr.Reddy's Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-773</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>250 mg/25mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Gland Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68083-279</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Meitheal Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71288-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 mg/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA211003</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Dr.Reddy's Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-771</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>175 mg/17.5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Gland Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68083-278</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Meitheal Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>71288-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA211002</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Fosun Pharma USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>72266-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-915</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>250 mg/25mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210892</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>45963-762</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206516</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin</name>
      <labeller>Sandoz Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0781-3201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>175 mg/17.5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203563</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin Calcium</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203576</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin Calcium</name>
      <labeller>Mylan Institutional LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67457-600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203576</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Levoleucovorin Calcium</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1572</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA207548</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Fusilev</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Fusilev</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Fusilev</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin Calcium</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin Calcium</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Khapzory</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Khapzory</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Khapzory</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Khapzory</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Fusilev</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Fusilev</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Fusilev</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin Calcium</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
    <mixture>
      <name>Levoleucovorin</name>
      <ingredients>Levoleucovorin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antidotes</category>
      <mesh-id>D000931</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Coenzymes</category>
      <mesh-id>D003067</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Detoxifying Agents for Antineoplastic Treatment</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Folate Analog</category>
      <mesh-id/>
    </category>
    <category>
      <category>Folic Acid Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Folic Acid and Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Formyltetrahydrofolates</category>
      <mesh-id>D005575</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Pigments, Biological</category>
      <mesh-id>D010860</mesh-id>
    </category>
    <category>
      <category>Protective Agents</category>
      <mesh-id>D020011</mesh-id>
    </category>
    <category>
      <category>Pteridines</category>
      <mesh-id>D011621</mesh-id>
    </category>
    <category>
      <category>Pterins</category>
      <mesh-id>D011622</mesh-id>
    </category>
    <category>
      <category>Tetrahydrofolates</category>
      <mesh-id>D013763</mesh-id>
    </category>
    <category>
      <category>Vitamin B Complex</category>
      <mesh-id>D014803</mesh-id>
    </category>
    <category>
      <category>Vitamins</category>
      <mesh-id>D014815</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>175 mg/3.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>300 mg/6mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg/10mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>175 mg/17.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>250 mg/25mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V03AF10">
      <level code="V03AF">Detoxifying agents for antineoplastic treatment</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
    <atc-code code="V03AF04">
      <level code="V03AF">Detoxifying agents for antineoplastic treatment</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1dfo</pdb-entry>
    <pdb-entry>1eqb</pdb-entry>
    <pdb-entry>1jol</pdb-entry>
    <pdb-entry>1jom</pdb-entry>
    <pdb-entry>1pj7</pdb-entry>
    <pdb-entry>1wop</pdb-entry>
    <pdb-entry>2vmy</pdb-entry>
    <pdb-entry>3sd3</pdb-entry>
    <pdb-entry>3suh</pdb-entry>
    <pdb-entry>3uwl</pdb-entry>
    <pdb-entry>4gta</pdb-entry>
    <pdb-entry>4lvv</pdb-entry>
    <pdb-entry>6qxs</pdb-entry>
    <pdb-entry>6qyq</pdb-entry>
    <pdb-entry>6r2e</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11596.pdf?1471463765</fda-label>
  <patents>
    <patent>
      <number>6500829</number>
      <country>United States</country>
      <approved>2002-12-31</approved>
      <expires>2022-03-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The serum concentration of Fosphenytoin can be decreased when it is combined with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The therapeutic efficacy of Raltitrexed can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The serum concentration of Levoleucovorin can be decreased when it is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be decreased when it is combined with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08898</drugbank-id>
      <name>Glucarpidase</name>
      <description>The serum concentration of the active metabolites of Levoleucovorin can be reduced when Levoleucovorin is used in combination with Glucarpidase resulting in a loss in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be decreased when it is combined with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The serum concentration of Primidone can be decreased when it is combined with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00205</drugbank-id>
      <name>Pyrimethamine</name>
      <description>The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The therapeutic efficacy of Dapsone can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The therapeutic efficacy of Trimethoprim can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The therapeutic efficacy of Methotrexate can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The therapeutic efficacy of Pemetrexed can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The therapeutic efficacy of Proguanil can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>The therapeutic efficacy of Trimetrexate can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03695</drugbank-id>
      <name>Piritrexim</name>
      <description>The therapeutic efficacy of Piritrexim can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04655</drugbank-id>
      <name>Metoprine</name>
      <description>The therapeutic efficacy of Metoprine can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06358</drugbank-id>
      <name>Iclaprim</name>
      <description>The therapeutic efficacy of Iclaprim can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08878</drugbank-id>
      <name>Aminopterin</name>
      <description>The therapeutic efficacy of Aminopterin can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12769</drugbank-id>
      <name>Lometrexol</name>
      <description>The therapeutic efficacy of Lometrexol can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12912</drugbank-id>
      <name>Nolatrexed</name>
      <description>The therapeutic efficacy of Nolatrexed can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13795</drugbank-id>
      <name>Brodimoprim</name>
      <description>The therapeutic efficacy of Brodimoprim can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14763</drugbank-id>
      <name>Cycloguanil</name>
      <description>The therapeutic efficacy of Cycloguanil can be decreased when used in combination with Levoleucovorin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>The serum concentration of Levoleucovorin can be decreased when it is combined with Colestipol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01629</drugbank-id>
      <name>5-fluorouridine</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with 5-fluorouridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03419</drugbank-id>
      <name>Uracil</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Uracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Tegafur.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The serum concentration of Levoleucovorin can be decreased when it is combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be decreased when it is combined with Levoleucovorin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.00e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-2.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2S)-2-{[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2S)-2-{[4-({[(6S)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>473.4393</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>473.165896125</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H23N7O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12-,13-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>VVIAGPKUTFNRDU-STQMWFEESA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>215.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>126.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>44.58</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>2.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>63606</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>149436</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347828002</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D04715</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>131714</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>286</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450198</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>FFO</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Levoleucovorin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1908841</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/levoleucovorin-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>https://www.drugs.com/levoleucovorin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11596</drugbank-id>
        <name>Levoleucovorin</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00528</drugbank-id>
        <name>5-Methyltetrahydrofolate</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0001838</id>
      <name>Serine hydroxymethyltransferase</name>
      <organism>Shigella flexneri</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P0A827" source="Swiss-Prot">
        <name>Serine hydroxymethyltransferase</name>
        <general-function>Pyridoxal phosphate binding</general-function>
        <specific-function>Catalyzes the reversible interconversion of serine and glycine with tetrahydrofolate (THF) serving as the one-carbon carrier. This reaction serves as the major source of one-carbon groups required for the biosynthesis of purines, thymidylate, methionine, and other important biomolecules. Also exhibits THF-independent aldolase activity toward beta-hydroxyamino acids, producing glycine and aldehydes, via a retro-aldol mechanism.</specific-function>
        <gene-name>glyA</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.45</theoretical-pi>
        <molecular-weight>45316.33</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="623">Shigella flexneri</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AE005674</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>24052975</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0A827</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GLYA_SHIFL</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.1.2.1</synonym>
          <synonym>SHMT</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011317|Serine hydroxymethyltransferase
MLKREMNIADYDAELWQAMEQEKVRQEEHIELIASENYTSPRVMQAQGSQLTNKYAEGYP
GKRYYGGCEYVDIVEQLAIDRAKELFGADYANVQPHSGSQANFAVYTALLEPGDTVLGMN
LAHGGHLTHGSPVNFSGKLYNIVPYGIDATGHIDYADLEKQAKEHKPKMIIGGFSAYSGV
VDWAKMREIADSIGAYLFVDMAHVAGLVAAGVYPNPVPHAHVVTTTTHKTLAGPRGGLIL
AKGGSEELYKKLNSAVFPGGQGGPLMHVIAGKAVALKEAMEPEFKTYQQQVAKNAKAMVE
VFLERGYKVVSGGTDNHLFLVDLVDKNLTGKEADAALGRANITVNKNSVPNDPKSPFVTS
GIRVGTPAITRRGFKEAEAKELAGWMCDVLDSINDEAVIERIKGKVLDICARYPVYA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011318|Serine hydroxymethyltransferase (glyA)
ATGTTAAAGCGTGAAATGAACATTGCCGATTATGATGCCGAACTGTGGCAGGCTATGGAG
CAGGAAAAAGTACGTCAGGAAGAGCACATCGAACTGATCGCCTCCGAAAACTACACCAGC
CCGCGCGTAATGCAGGCGCAGGGTTCTCAGCTGACCAACAAATATGCTGAAGGTTATCCG
GGCAAACGCTACTACGGCGGTTGCGAGTATGTTGATATCGTTGAACAACTGGCGATCGAT
CGTGCGAAAGAACTGTTCGGCGCTGACTACGCTAACGTCCAGCCGCACTCCGGCTCCCAG
GCTAACTTTGCGGTCTACACCGCGCTGCTGGAACCAGGTGATACCGTTCTGGGTATGAAC
CTGGCGCATGGCGGTCACCTGACTCACGGTTCTCCGGTTAACTTCTCCGGTAAACTGTAC
AACATCGTTCCTTACGGTATCGATGCTACCGGTCATATCGATTACGCCGATCTGGAAAAA
CAAGCCAAAGAACACAAGCCGAAAATGATTATCGGTGGTTTCTCTGCATATTCCGGCGTG
GTTGACTGGGCGAAAATGCGTGAAATCGCTGACAGCATCGGTGCTTATCTGTTCGTTGAT
ATGGCGCACGTTGCGGGCCTGGTTGCTGCTGGCGTCTACCCGAACCCGGTTCCTCATGCT
CACGTTGTTACTACCACCACTCACAAAACCCTGGCGGGTCCGCGCGGCGGCCTGATCTTG
GCGAAAGGTGGTAGCGAAGAGCTGTACAAAAAACTGAACTCTGCCGTTTTCCCTGGTGGT
CAGGGCGGTCCGTTGATGCACGTAATCGCCGGTAAAGCGGTTGCTCTGAAAGAAGCGATG
GAGCCTGAGTTCAAAACTTACCAGCAGCAGGTCGCGAAAAACGCTAAAGCGATGGTAGAA
GTGTTCCTCGAGCGCGGCTACAAAGTGGTTTCCGGCGGCACTGATAACCACCTGTTCCTG
GTTGATCTGGTTGATAAAAACCTGACCGGTAAAGAAGCAGACGCCGCTCTGGGCCGTGCT
AACATCACCGTCAACAAAAACAGCGTACCGAACGATCCGAAGAGCCCGTTTGTGACCTCC
GGTATTCGTGTAGGTACTCCGGCGATTACCCGTCGCGGCTTTAAAGAAGCCGAAGCGAAA
GAACTGGCTGGCTGGATGTGTGACGTGCTGGACAGCATCAATGATGAAGCCGTTATCGAG
CGCATCAAAGGTAAAGTTCTCGACATCTGCGCACGTTACCCGGTTTACGCATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00464</identifier>
            <name>SHMT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycine hydroxymethyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycine biosynthetic process from serine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tetrahydrofolate interconversion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0002010</id>
      <name>Dihydrofolate reductase</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P0ABQ4" source="Swiss-Prot">
        <name>Dihydrofolate reductase</name>
        <general-function>Nadp binding</general-function>
        <specific-function>Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.</specific-function>
        <gene-name>folA</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.61</theoretical-pi>
        <molecular-weight>17999.21</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J01609</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>146006</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0ABQ4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DYR_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.5.1.3</synonym>
          <synonym>tmrA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019220|Dihydrofolate reductase
MISLIAALAVDRVIGMENAMPWNLPADLAWFKRNTLNKPVIMGRHTWESIGRPLPGRKNI
ILSSQPGTDDRVTWVKSVDEAIAACGDVPEIMVIGGGRVYEQFLPKAQKLYLTHIDAEVE
GDTHFPDYEPDDWESVFSEFHDADAQNSHSYCFEILERR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019221|Dihydrofolate reductase (folA)
ATGATCAGTCTGATTGCGGCGTTAGCGGTAGATCGCGTTATCGGCATGGAAAACGCCATG
CCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAAACCCGTG
ATTATGGGCCGCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGACGCAAAAATATT
ATCCTCAGCAGTCAACCGGGTACGGACGATCGCGTAACGTGGGTGAAGTCGGTGGATGAA
GCCATCGCGGCGTGTGGTGACGTACCAGAAATCATGGTGATTGGCGGCGGTCGCGTTTAT
GAACAGTTCTTGCCAAAAGCGCAAAAACTGTATCTGACGCATATCGACGCAGAAGTGGAA
GGCGACACCCATTTCCCGGATTACGAGCCGGATGACTGGGAATCGGTATTCAGCGAATTC
CACGATGCTGATGCGCAGAACTCTCACAGCTATTGCTTTGAGATTCTGGAGCGGCGGTAA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00186</identifier>
            <name>DHFR_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dihydrofolate reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NADP binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>one-carbon metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tetrahydrofolate biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>